Search research articles
Contact Us
Filters
Showing results (81-90 of 113) with videos related to
Page
of 12
Sort By:
American Journal of Hematology
|
March 13, 2025
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Saubia Fathima, Maymona Abdelmagid, Ali Alsugair, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
American Journal of Hematology
|
December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology
|
December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Journal of Clinical Pathology
|
June 26, 2025
Karyotypic clonal fraction predicts adverse outcome in <i>TP53</i>-mutated myeloid neoplasms: an International <i>TP53</i> investigators Network (iTiN) study
Madhavi Pandiri, Anna Stengel, Jingjing Zhang, et al.
Cancer
|
December 19, 2025
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study
Irfan Yasin, Anna Stengel, Haipeng Shao, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Blood Cancer Journal
|
April 6, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Saubia Fathima, Lior Rokach, Nour Ghosoun, et al.
Blood Advances
|
March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
Anmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
American Journal of Hematology
|
July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Reem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 113) with videos related to
Sort By:
Page
of 12
American Journal of Hematology
|
March 13, 2025
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Saubia Fathima, Maymona Abdelmagid, Ali Alsugair, et al.
Leukemia & Lymphoma
|
October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
Talha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
American Journal of Hematology
|
December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology
|
December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Journal of Clinical Pathology
|
June 26, 2025
Karyotypic clonal fraction predicts adverse outcome in <i>TP53</i>-mutated myeloid neoplasms: an International <i>TP53</i> investigators Network (iTiN) study
Madhavi Pandiri, Anna Stengel, Jingjing Zhang, et al.
Cancer
|
December 19, 2025
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study
Irfan Yasin, Anna Stengel, Haipeng Shao, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Blood Cancer Journal
|
April 6, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Saubia Fathima, Lior Rokach, Nour Ghosoun, et al.
Blood Advances
|
March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
Anmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
American Journal of Hematology
|
July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Reem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Page
of 12